Cell line · CVCL_2063
Papers122
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 122
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| HSAT3 lncRNA regulates replication re-initiation and colocalizes with TOP2A under stress conditions. | Epigenetics Chromatin | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Longitudinal Assessment of EGFR and MET Transcriptional Activity Using Cell-Free Chromatin Immunoprecipitation in Two Patients with EGFR-Mutated Non-Small Cell Lung Cancer. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis. | Integr Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LncRNA MNX1-AS1 drives the progression of non-small cell lung cancer and serves as a ceRNA to target COMMD8 by sponging miR-218-5p. | J Mol Histol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A USP15/KRT17-associated 13-gene prognostic cluster and functional validation in EGFR-mutant lung adenocarcinoma. | Respir Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8+ T-cell activation. | BMC Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC. | Cell Oncol (Dordr) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8+ T Cell Anti-Tumor Immunity. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma. | Respir Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial translocation of MDM2 and TFAM reprograms metabolism in treatment-refractory cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| C1RL-AS1/microRNA-424-5p/adrenoceptor β2 axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis. | PLoS One | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2063/papers